Enlivex (ENLV) Other Non-Current Liabilities (2017 - 2025)
Enlivex (ENLV) posted quarterly Other Non-Current Liabilities of $426000.0 for Q3 2025, up 1.67% year-over-year from $419000.0 in Q3 2024, and up 97.22% quarter-over-quarter from $216000.0 in Q2 2025.
Enlivex (ENLV) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
Enlivex's Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $426000.0 for Q3 2025.
- In Q3 2025, Other Non-Current Liabilities rose 1.67% year-over-year to $426000.0; the TTM figure through Sep 2025 stood at $426000.0 (up 1.67% YoY), while the FY2024 annual figure was $299000.0, down 56.41% from the prior year.
- Other Non-Current Liabilities for Q3 2025 stood at $426000.0, up from $216000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $5.4 million in Q4 2021, with the low at $216000.0 in Q2 2025.
- The 5-year median for Other Non-Current Liabilities is $686000.0 (2023), against an average of $2.4 million.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities soared 1063.92% in 2022, then slumped 89.03% in 2024.
- Enlivex's Other Non-Current Liabilities stood at $5.4 million in 2021, then dropped by 22.17% to $4.2 million in 2022, then slumped by 83.64% to $686000.0 in 2023, then sank by 56.41% to $299000.0 in 2024, then soared by 42.47% to $426000.0 in 2025.
- Business Quant data shows ENLV's Other Non-Current Liabilities at $426000.0 in Q3 2025, $216000.0 in Q2 2025, and $264000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 426,000.00 |
| Jun 30, 2025 | 216,000.00 |
| Mar 31, 2025 | 264,000.00 |
| Dec 31, 2024 | 299,000.00 |
| Sep 30, 2024 | 419,000.00 |
| Jun 30, 2024 | 499,000.00 |
| Mar 31, 2024 | 587,000.00 |
| Dec 31, 2023 | 686,000.00 |
| Sep 30, 2023 | 3.82 Mn |
| Jun 30, 2023 | 3.70 Mn |
| Mar 31, 2023 | 4.00 Mn |
| Dec 31, 2022 | 4.19 Mn |
| Sep 30, 2022 | 4.61 Mn |
| Jun 30, 2022 | 4.64 Mn |
| Mar 31, 2022 | 5.23 Mn |
| Dec 31, 2021 | 5.39 Mn |
| Sep 30, 2021 | 5.35 Mn |
| Jun 30, 2021 | 405,000.00 |
| Mar 31, 2021 | 449,000.00 |
| Dec 31, 2020 | 499,000.00 |